ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

RFA: Long-Term Cancer Survivors

September 12, 1997

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

In Brief: Peter Fischinger Names NCI Deputy Director; ACR Moves Headquarters To Washington Area

November 8, 1985

NCI To Recompete Drug Discovery Groups In 2003 As Program Nears Its 20th Year

November 29, 2002

CAN-DIAL Test Generates 16,000 Calls for Cancer Information

December 13, 1974

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

May 8, 2013